The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer—Further observations from the IMPACT solid study
Johanna Mäenpää(Tampere University Hospital), Shailendra Verma(University of Lucknow), Frans Erdkamp, Kate Bendall(Amgen (United Kingdom)), Florian D. Vogl(Amgen (United States)), Ioannis Varthalitis(Chania General Hospital ”St. George”), Krzysztof Krzemieniecki(Jagiellonian University), Henrik Lindman(Uppsala University), Andreas Trojan(Immunologie-Zentrum Zürich)
Cited by 10
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260